- TV Footage
- Financial Reports
- Newsletter Overview
- Social Media
- Media Contact
Monheim, June 3, 2019 – Bayer Animal Health launched Advantage™ during the 11th East and West Small-Animal Veterinary Conference in Xiamen, China. Advantage™ has been registered in China for the treatment and prevention of flea infestations, and the treatment of lice infestations. The product is currently authorized worldwide in more than 75 countries. Since its initial launch, over 150 million pets have been treated with Advantage™ worldwide.
“Advantage™ is not only a reliable and convenient product, it’s an effective choice in flea protection for cats and dogs with a proven track record of more than 20 years,” says Bin Liu, Head of the Companion Animal Business Unit at Bayer Animal Health China. “With the market entry of Advantage™ in China, we offer veterinarians and pet owners an international brand available at a competitive price in order to target a broader audience and to help increase pet owners’ compliance in China.”
Latest market data describe an enormous increase in pet ownership and growth of urban populations. With the increasing numbers of pets, there are also more opportunities for parasites to flourish. Especially in the mega-cities like Shanghai or Beijing, where pets are seen as part of the family, the Advantage™ launch provides a real opportunity to pet owners. “Advantage™ is a very convenient treatment which protects the pet,” explains Bin Liu. “It is essential for pet owners to know that parasite protection is of vital importance to ensure the health of a pet, and ultimately, that of the family. Advantage is a monthly topical flea treatment that works through contact so fleas don’t have to bite to die and this helps prevent disease transmission.”
This week, the effective flea control for cats and dogs was presented to 150 key veterinary customers. SungShik Shin, Professor of Veterinary Parasitology, College of Veterinary Medicine at Chonnam National University in South Korea spoke at this event about flea infestation in dogs and cats as an important public health concern.
“Fleas can cause serious health problems such as flea allergy dermatitis (FAD),” Professor Shin said. “Also in rapidly growing markets like China, effective flea control is important to protect the health of cats and dogs.”
To find out more please read at http://animalhealth.bayer.com/ and https://mypetandi.bayer.com/uk/advantage/dog-advantage-flea-treatment-dogs.
Advantage™ for cats and dogs is a convenient, monthly topical flea control for cats and dogs that kills fleas through contact, so they do not have to bite a dog or cat to die. Simple, monthly applications will help cats and dogs to get rid of fleas and in the prevention of secondary problems like Flea Allergy Dermatitis (FAD). Advantage™ is a spot-on treatment that is easy to apply, fast and effective and protects the pet. The topical formula of Advantage™ spreads into the lipid layer of the skin and fur and remains effective for 28 days.
Flea infestations are more than just a nuisance; they also pose a very real threat to both pets and humans as they can transmit serious diseases. These diseases have become more frequently diagnosed and more geographically widespread, increasing both the danger posed to pets and the risk posed to humans.
Fleas are the most common ectoparasite in cats and dogs and are capable of spreading and/or causing a number of diseases that affect cats, dogs and humans, including tapeworm, flea allergy dermatitis (FAD), bartonellosis and endemic typhus. The most effective disease prevention technique is to stop parasites from biting, reducing the possibility of disease transmission.
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros. For more information, go to www.bayer.com.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.